Based on the information provided, it seems that Homology Medicines (FIXX) has experienced a significant decline of -32.09% over the course of one month. This puts the stock among the top monthly losers among penny stocks. Additionally, A.I.dvisor's analysis of the biotechnology industry shows that a majority of stocks (80.86%) exhibited a downtrend over the last month.
In terms of technical indicators, FIXX has recently seen its MACD Histogram turn negative on March 09, 2023. This is a bearish signal that suggests the stock could continue to decline in the future. According to Tickeron's A.I.dvisor, out of the 46 instances where the MACD turned negative, 44 resulted in the stock moving lower in the following days. This gives the odds of a downward move a 90% chance.
Given these technical indicators and market trends, it may be wise for investors to exercise caution when considering Homology Medicines (FIXX) as a potential investment option. It is important to conduct further research and analysis before making any investment decisions.
On June 06, 2023, the Stochastic Oscillator for FIXX moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 64 instances where the indicator left the oversold zone. In of the 64 cases the stock moved higher in the following days. This puts the odds of a move higher at over .
The Momentum Indicator moved above the 0 level on June 06, 2023. You may want to consider a long position or call options on FIXX as a result. In of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for FIXX just turned positive on June 06, 2023. Looking at past instances where FIXX's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .
FIXX moved above its 50-day moving average on June 06, 2023 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for FIXX crossed bullishly above the 50-day moving average on May 18, 2023. This indicates that the trend has shifted higher and could be considered a buy signal. In of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where FIXX advanced for three days, in of 257 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 149 cases where FIXX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FIXX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.377) is normal, around the industry mean (25.115). P/E Ratio (0.000) is within average values for comparable stocks, (123.628). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.372). Dividend Yield (0.000) settles around the average of (0.030) among similar stocks. P/S Ratio (17.762) is also within normal values, averaging (308.870).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. FIXX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FIXX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of genetic medicines
A.I.dvisor indicates that over the last year, FIXX has been loosely correlated with BOLT. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if FIXX jumps, then BOLT could also see price increases.
|BOLT - FIXX|
|ALLO - FIXX|
|DTIL - FIXX|
|PASG - FIXX|
|BEAM - FIXX|